Episode Details
Back to Episodes
Pharmaceutical Executive Daily: Rigel Pharmaceuticals Enters an Exclusive Global Licensing Agreement with Arvinas and Pfizer for Veppanu
Published 1 week ago
Description
In today's Pharmaceutical Executive Daily, Rigel Pharmaceuticals enters an exclusive global licensing agreement with Arvinas and Pfizer for Veppanu, Eli Lilly releases data from two late-phase trials showing patients maintained meaningful weight loss after transitioning from higher-dose injectable GLP-1 therapies, and Hope Mueller argues that true pharmaceutical expertise is defined not just by having answers but by recognizing when you need a reset.